ClinicalTrials.gg
RecruitingNCT07711132CPP-ACPUpdated Jul 17, 2026

Remineralizing Effect of Nano-eggshell, Casein Phosphopeptide Amorphous Calcium Phosphate (CPP-ACP), and Sodium Fluoride on Initial Enamel Caries

An interventional study of nano-eggshell varnish and Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)Dental Paste in Initial Dental Caries, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to participants aged 15 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2025, registered May 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
15 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Dental Caries by Mansoura University — 5 open to participants now, 12 under way, none of them phase 3. Dental Caries · Mansoura University.

Planned enrollment
3rd of 19
90 · median 40
Started
2025
with 5 others
No phase
19 of 19
5 open now
Primary completion
2026-12
later than 6 of 11 live
Registered
15th of 19
by date

Among the 19 studies in Dental Caries by Mansoura University, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2025, is one of 19 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 15th registered.

Dental Caries

1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

5 of the 19 studies in Dental Caries by Mansoura University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 15 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Dental Caries by Mansoura University, or all of them as a file.
02

Study summary

This randomized controlled clinical trial aims to evaluate and compare the remineralizing effect of nano-eggshell varnish, CPP-ACP paste (GC Tooth Mousse), and sodium fluoride varnish on initial enamel caries among adolescents aged 15-20 years.

Participants will be randomly allocated into three groups. Remineralization and caries activity will be assessed using DIAGNOdent readings, International Caries Classification and Management System (ICCMS) criteria, and the decayed, missed, and filled surfaces (DMFS) index over a 12-month follow-up period.

03

Conditions studied

  • Initial Dental Caries

Browse trials for

Keywords

  • Remineralization
  • Nano eggshell
  • initial enamel caries
04

Who can participate

Ages eligible
15 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients' ages should be 15-20 years. Patients should have at least three to four teeth with ICDAS II scores of 1-2. Patients should have moderate-to-high caries risk.

Exclusion criteria

Exclusion Criteria:

Known to one of the components of the material under study. Systemic disorders or medication interfering with normal salivary flow.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    nano-eggshell varnish group 1

    Nano-eggshell varnish will be professionally applied to the teeth surfaces every 3 months according to the manufacturer's instructions. Participants will be instructed to avoid eating or drinking for at least 30 minutes after application.

    Drug: nano-eggshell varnish

  • Experimental
    Casein phosphopeptide amorphous calcium phosphate (CPP-ACP) as GC tooth mousse group 2

    Participants will be instructed to apply CPP-ACP (GC tooth mousse) daily after tooth brushing at bedtime. The material will be kept on the tooth surfaces for at least 3 minutes before rinsing.

    Drug: Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)Dental Paste

  • Active comparator
    Sodium fluoride varnish (5%) group 3

    Sodium fluoride varnish (5%) will be professionally applied every 3 months according to manufacturer instructions. Participants will be instructed to avoid eating or drinking for at least 30 minutes after application.

    Drug: Sodium Fluoride Varnish (5%)

Interventions

  • Drugnano-eggshell varnish

    Nano-eggshell varnish is applied topically to tooth surfaces every 3 months, according to manufacturer instructions, to promote the remineralization of initial enamel caries.

  • DrugCasein phosphopeptide-amorphous calcium phosphate nanocomplexStudies of Casein phosphopeptide-amorphous calcium phosphate nanocomplexCasein phosphopeptide-amorphous calcium phosphate nanocomplex pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) paste was applied daily by participants after tooth brushing at bedtime and left on teeth for at least 3 minutes before rinsing.

  • DrugSodium Fluoride Varnish (5%)

    5% sodium fluoride varnish is applied topically every 3 months according to manufacturer instructions as a controlled remineralizing agent.

06

What researchers measure

Primary outcomes

  1. Change in remineralization of initial enamel caries

    Change in remineralization of initial enamel caries measured by DIAGNOdent readings from baseline to 12 months. When the DIAGNOdent reading decreases, it means good remineralization ability.

    Time frame: Baseline to 12 months

  2. Change in DIAGNOdent readings

    The DIAGNOdent device will be used to quantify changes in enamel demineralization and remineralization over time. Measurements will be recorded at different follow-up intervals

    Time frame: Baseline, 3, 6, 9, and 12 months

Secondary outcomes

  1. Caries activity assessment using ICCMS criteria

    Caries activity will be assessed using the International Caries Classification and Management System (ICCMS) criteria. Lesions will be classified as active or inactive based on surface texture, appearance, and plaque stagnation area

    Time frame: Baseline, 3, 6, 9, and 12 months

  2. Change in the Decayed, Missing, and Filled Surfaces (DMFS) index

    Dental caries experience will be evaluated using the Decayed, Missing, and Filled Surfaces (DMFS) index at baseline and after 6 and 12 months to assess overall changes in caries experience.

    Time frame: baseline, after 6 and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sarhan M, El Baz M, Hamza O. Remineralization effect of eggshell powder on post-orthodontic white spot lesions compared to CPP-ACP: a randomized controlled clinical trial. Egyptian Dental Journal. 2021. 67(3): 2701-2710.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data available upon request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 470 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 12 months is below that.

Counting every sponsor, half of 503 studies reached it within 15 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Jul 17, 2026
StartActual
Dec 20, 2025
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07711132
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Dec 20, 2025
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Jul 17, 2026

Study contacts

Ghada E Elhindawy
Contact
ghada.ezzat91@yahoo.com
00201102668577

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Casein phosphopeptide-amorphous calcium phosphate nanocomplex

Start the discussion